{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-122282","form_type":"8-K","ticker":"ALMS","cik":"0001847367","company_name":"ALUMIS INC.","filed_at":"2024-11-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.018647+00:00","generated_at":"2026-05-29T19:07:26.243822+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"medium","headline":"Alumis updates LUMUS Phase 2 trial timeline on ClinicalTrials.gov","bullets":["Revised primary completion and study completion dates for LUMUS trial (ESK-001 in SLE) posted November 22, 2024.","LUMUS is a global, randomized, double-blind, placebo-controlled Phase 2 trial.","Company states the revisions conform with prior SEC filings and public guidance.","No specific new dates or financial impact disclosed in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-122282","json":"https://secwatch.observer/filing/0001104659-24-122282.json","markdown":"https://secwatch.observer/filing/0001104659-24-122282.md","text":"https://secwatch.observer/filing/0001104659-24-122282.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847367/000110465924122282/0001104659-24-122282-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847367/000110465924122282/tm2429434d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T19:07:26.243822+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}